Secretases as therapeutic targets in Alzheimer's disease: Patents 2000 - 2004

Expert Opinion on Therapeutic Patents

Volumn 14, Issue 10, 2004, Pages 1403-1420

  Larner, A J ^a  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

secretase; secretase; secretase; Alzheimer's disease; Amyloid peptide; Inhibitor

Indexed keywords

ALDEHYDE DERIVATIVE; ALIPHATIC AMINE; ALPHA SECRETASE; ALPHA SECRETASE INHIBITOR; AMYLOID PRECURSOR PROTEIN; AROMATIC COMPOUND; BENZAMIDE DERIVATIVE; BETA SECRETASE; BETA SECRETASE INHIBITOR; BMS 299897; ETHYLENE DERIVATIVE; FUSED HETEROCYCLIC RINGS; GAMMA SECRETASE; GAMMA SECRETASE INHIBITOR; GLUTARIC ACID DERIVATIVE; HYDRAZINE DERIVATIVE; LACTAM DERIVATIVE; LETEPRINIM; LY 450139; MACROCYCLIC COMPOUND; MIFEPRISTONE; NOOTROPIC AGENT; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; QUINALDINE DERIVATIVE; S ADENOSYLMETHIONINE; STATINE DERIVATIVE; SUCCINIC ACID DERIVATIVE; TALSACLIDINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ALZHEIMER DISEASE; CLINICAL TRIAL; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SPECIFICITY; HUMAN; NONHUMAN; PATENT; PATHOGENESIS; PROTEIN METABOLISM; PUBLISHING; REVIEW;

EID: 5744225747     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.14.10.1403     Document Type: Review

References (84)

1. LARNER AJ, ROSSOR MN: Alzheimer's disease: towards therapeutic manipulation of the amyloid precursor protein and amyloid β-peptides. Expert Opin. Ther. Patents (1997) 7 10):1115-1127.
2. LARNER AJ: Alzheimer's disease: targets for drug development. Mini Rev. Med. Chem. (2002) 2:1-9.
3. HARDY J, ALLSOP D: Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol. Sci. (1991) 12:383-388.
4. ARRIAGADA PV, GROWDON JH, HEDLEY-WHITE ET, HYMAN BT: Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology (1992) 42:631-639.
5. McLEAN CA, CHERNY RA, FRASER FW et al.: Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease. Ann. Neurol. (1999) 46:860-866.
6. LUE LF, KUO YM, ROHER AE et al.: Soluble amyloid β peptide concentration as a predictor of synaptic change in Alzheimer's disease. Am. J. Pathol. (1999) 155:853-862.
7. NÄSLUND J, HAROUTUNIAN V, MOHS R et al.: Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA (2000) 283:1571-1577.
8. SISODIA SS: β-Amyloid precursor protein cleavage by a membrane-bound protease. Proc. Natl. Acad. Sci. USA (1992) 89 6075-6079.
9. LU DC, RABIZADEH S, CHANDRA S et al.: A second cytotoxic proteolytic peptide derived from amyloid β-protein precursor. Nat. Med. (2000) 6:397-404.
10. LARNER AJ: Hypothesis: physiological and pathological interrelationships of amyloid β-peptide and the amyloid precursor protein. Bioessays (1995) 17:819-824.
11. LORENZO A, YUAN M, ZHANG Z et al.: Amyloid β interacts with the amyloid precursor protein: a potential toxic mechanism in Alzheimer's disease. Nat. Neurosci. (2000) 3:460-464.
12. LU DC, SHAKED GM, MASLIAH E, BREDESEN DE, KOO EH: Amyloid β-protein toxicity mediated by the formation of amyloid-β protein precursor complexes. Ann. Neurol. (2003) 54:781-789.
13. GAMES D, ADAMS D, ALESSANDRINI R et al.: Alzheimer-type neuropathology in transgenic mice overexpressing V717F β-amyloid precursor protein. Nature (1995) 373:523-527.
14. HSIAO K, CHAPMAN P, NILSEN S et al.: Correlative memory deficits, Aβ elevation, and amyloid plaques in transgenic mice. Science (1996) 274:99-102.
15. WOLFE MS: The secretases of Alzheimer's disease. Curr. Top. Dev. Biol. (2003) 54:233-261.
16. VASSAR R, BENNETT BD, BABU-KHAN S et al.: β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science (1999) 286:735-741.
17. SINHA S, ANDERSON JP, BARBOUR R et al.: Purification and cloning of amyloid precursor protein β-secretase from human brain. Nature (1999) 402:537-540.
18. YAN R, BIENKOWSKI MJ, SHUCK ME et al.: Membrane-anchored aspartyl protease with Alzheimer's disease β -secretase activity. Nature (1999) 402:533-537.
19. HUSSAIN I, POWELL D, HOWLETT DR et al.: Identification of a novel aspartic protease (Asp2) as β-secretase. Mol. Cell. Neurosci. (1999) 14:419-427.
20. SKOVRONSKY DM, LEE VM-Y: β-Secretase revealed: starting gate for race to novel therapies for Alzheimer's disease. Trends Pharmacol. Sci. (2000) 21:161-163.
21. CAI H, WANG Y, MCCARTHY D et al.: BACE1 is the major β-secretase for generation of Aβ peptides by neurons. Nat. Neurosci. (2001) 4:233-234.
22. FARZAN M, SCHNITZLER CE, VASILIEVA N, LEUNG D, CHOE H: BACE2, a β-secretase homolog, cleaves at the β-site and within the amyloid-β region of the amyloid β precursor protein. Proc. Natl. Acad. Sci. USA (2000) 97:9712-9717.
23. SOLANS A, ESTIVILL X, DE LA LUNA S: A new aspartyl protease on 21q22.3, BACE2, is highly similar to Alzheimer's amyloid precursor protein β-secretase. Cytogenet. Cell Genet. (2000) 89 177-184.
24. BENNETT BD, BABU-KHAN S, LOELOFF R et al.: Expression analysis of BACE2 in brain and peripheral tissues. J. Biol. Chem. (2000) 275:20647-20651.
25. HOLSINGER RMD, MCLEAN CA, BEYREUTHER K, MASTERS CL, EVIN G: Increased expression of the amyloid precursor β-secretase in Alzheimer's disease. Ann. Neurol. (2002) 51:783-786.
26. FUKUMOTO H, CHEUNG BS, HYMAN BT, IRIZARRY MC: β-Secretase protein and activity are increased in the neocortex in Alzheimer's disease. Arch. Neurol. (2002) 59:1381-1389.
27. TYLER SJ, DAWBARN D, WILCOCK GK, ALLEN SJ: α- and β-secretase: profound changes in Alzheimer's disease. Biochem. Biophys. Res. Commun. (2002) 299:373-376.
28. YANG LB, LINDHOLM K, YAN R et al.: Elevated β-secretase expression and enzymatic activity detected in sporadic Alzheimer's disease. Nat. Med. (2003) 9:3-4.
29. GATTA LB, ALBERTINI A, RAVID R, FINAZZI D: Levels of β-secretase BACE and α-secretase ADAM10 mRNAs in Alzheimer hippocampus. Neuroreport (2002) 15:2031-2033.
30. LUO Y, BOLON B, KAHN S et al.: Mice deficient in BACE1, the Alzheimer's β-secretase, have normal phenotype and abolished β-amyloid generation. Nat. Neurosci. (2001) 4:231-232.
31. ROBERDS SL, ANDERSON J, BASI G et al.: BACE knockout mice are healthy despite lacking the primary β-secretase activity in brain: implications for Alzheimer's disease therapeutics. Hum. Mol. Genet. (2001) 10:1317-1324.
32. HARRISON SM, HARPER AJ, HAWKINS J et al.: BACE1 (β-secretase) transgenic and knockout mice: identification of neurochemical deficits and behavioral changes. Mol. Cell. Neurosci. (2003) 24:646-655.
33. LICHTENTHALER SF, DOMINGUEZ DI, WESTMEYER GG et al.: The cell adhesion protein P-selectin glycoprotein ligand-1 is a substrate for the aspartyl protease BACE1. J. Biol. Chem. (2003) 278 48713-48719.
34. DE STROOPER B, SAFTIG P, GAESSAERTS K et al.: Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature (1998) 391:387-390.
35. KIMBERLY WT, LAVOIE MJ, OSTASZEWSKI BL et al.: γ-Secretase is a membrane protein complex comprised of presenilin, nicastrin, Aph-1, and Pen-2. Proc. Natl. Acad. Sci. USA (2003) 100:6382-6387.
36. DE STROOPER B: Aph-1, Pen-2, and nicastrin with presenilin generate an active γ-secretase complex. Neuron (2003) 38 9-12.
37. XU M, LIA MT, HUANG Q et al.: γ-Secretase: characterization and implication for Alzheimer's disease therapy. Neurobiol. Aging (2002) 23:1023-1030.
38. HAASS C, STEINER H: Alzheimer's disease γ-secretase: a complex story of GxGD-type presenilin proteases. Trends Cell Biol. (2002) 12:556-562.
39. SELKOE D, KOPAN R: Notch and presenilin: regulated intramembrane proteolysis links development and degeneration. Ann. Rev. Neurosci. (2003) 26:565-597.
40. SCHEUNER D, ECKMAN C, JENSEN M et al.: Secreted amyloid β-protein similar to that in the amyloid plaques of Alzheimer's disease is increased in vivo by the presenilin-1 and -2 and APP mutations linked to familial Alzheimer's disease. Nat. Med. (1996 2 864-870.
41. SCHROETER EH, ILAGAN MX, BRUNKAN AL et al.: A presenilin dimer at the core of the γ-secretase enzyme: insights from parallel analysis of Notch-1 and APP proteolysis. Proc. Natl. Acad. Sci. USA (2003) 100:13075-13080.
42. DERMAUT B, KUMAR-SINGH S, ENGELBORGHS S et al.: A novel presenilin-1 mutation associated with Pick's disease but not β -amyloid plaques. Ann. Neurol. (2004) 55:617-626.
43. SHEN J, BRONSON RT, CHEN DF et al.: Skeletal and CNS defects in presenilin-1-deficient mice. Cell (1997) 89 629-639.
44. WOLFE MS, CITRON M, DIEHL TS, XIA W, DONKOR IO, SELKOE DJ: A substrate-based difluoro ketone selectively inhibits Alzheimer's γ-secretase activity. J. Med. Chem. (1998) 41:6-9.
45. DOVEY HF, JOHN V, ANDERSON JP et al.: Functional γ-secretase inhibitors reduce β-amyloid peptide levels in brain. J. Neurochem. (2001) 76:173-181.
46. LANZ TA, HIMES CA, PALLANTE G et al.: The γ-secretase inhibitor N-(N-(3,5-difluorophenacetyl)-L-alanyl)-S phenylglycine t-butyl ester reduces Aβ levels in vivo in plasma and cerebrospinal fluid in young (plaque-free) and aged (plaque-bearing) Tg2576 mice. J. Pharmacol. Exp. Ther. (2003) 305:864-871.
47. MARJAUX E, HARTMANN D, DE STROOPER B: Presenilins in memory, Alzheimer's disease, and therapy. Neuron (2004) 42:189-192.
48. WONG GT, MANFRA D, POULET FM et al.: Chronic treatment with the γ-secretase inhibitor LY-411,575 inhibits β-amyloid peptide production and alters lymphopoiesis and intestinal cell differentation. J. Biol. Chem. (2004) 279:12876-12882.
49. SKOVRONSKY DM, MOORE DB, MILLA ME, DOMS RW, LEE VM-Y: Protein kinase C-dependent α-secretase competes with β-secretase for cleavage of amyloid-β precursor protein in the transgolgi network. J. Biol. Chem. (2000) 275:2568-2575.
50. MASASHI A, HATTORI C, SZABO B et al.: Putative function of ADAM9, ADAM10, and ADAM17 as APP α-secretase. Biochem. Biophys. Res. Commun. (2003) 301:231-235.
51. ALLINSON TMJ, PARKIN ET, TURNER AJ, HOOPER NM: ADAMs family members as amyloid precursor protein α-secretases. J. Neurosci. Res. (2003) 74:342-352.
52. POSTINA R, SCHROEDER A, DEWACHTER I et al.: A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer's disease mouse model. J. Clin. Invest. (2004) 113:1456-1464.
53. HARTMANN D, DE STROOPER B, SERNEELS L et al.: The disintegrin/metalloproteinase ADAM10 is essential for Notch signalling but not for α-secretase activity in fibroblasts. Hum. Mol. Genet. (2002) 11:2615-2624.
54. KOJRO E, GIMPL G, LAMMICH S, MARZ W, FAHRENHOLZ F: Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM10. Proc. Natl. Acad. Sci. USA (2001) 98 5815-5820.
55. WOLOZIN B, KELLMAN W, RUOSSEAU P, CELESIA GG, SIEGEL G: Decreased prevalence of Alzheimer's disease associated with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arch. Neurol. (2000) 57:1439-1443.
56. JICK H, ZORNBERG GL, JICK SS, SESHADRI S, DRACHMAN DA: Statins and the risk of dementia. Lancet (2000) 356 1627-1631.
57. ROCKWOOD K, KIRKLAND S, HOGAN DB et al.: Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch. Neurol. (2002) 59 223-227.
58. ZAMRINI E, MCGWIN G, ROSEMAN JM: Association between statin use and Alzheimer's disease. Neuroepidemiology (2004) 23 94-98.
59. TUNG JS, DAVIS DL, ANDERSON JP et al.: Design of substrate-based inhibitors of human β-secretase. J. Med. Chem. (2002) 45:259-262.
60. NO AUTHORS LISTED: Statin-derived tetrapeptide inhibitors of β-secretase. Expert Opin. Ther. Patents (2001) 11 6):1047-1050.
61. HOM RK, FANG LY, MAMO S et al.: Design and synthesis of statine-based permeable peptidomimetic inhibitors of human β secretase. J. Med. Chem. (2003) 46:1799-1802.
62. HOM RK, GAILUNAS AF, MAMO S et al.: Design and synthesis of hydroxyethylene-based peptidomimetic inhibitors of human β-secretase. J. Med. Chem. (2004) 47:158-164.
63. ABBENANTE G, KOVACS DM, LEUNG DL, CRAIK DJ, TANZI RE, FAIRLIE DP: Inhibitors of β-amyloid formation based on the β-secretase cleavage site. Biochem. Biophys. Res. Commun. (2000) 268:133-135.
64. ERMOLIEFF J, LOY JA, KOELSCH G, TANG J: Proteolytic activation of recombinant pro-memapsin 2 (pro-β-secretase) studied with new fluorogenic substrates. Biochemistry (2000) 39 12450-12456 [Erratum Biochemistry (2000) 39:16263].
65. SHEARMAN MS, BEHER D, CLARKE EE et al.: L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid β-protein precursor γ-secretase activity. Biochemistry (2000) 39:8698-8704.
66. ZHANG L, SONG L, TERRACINA G, LIU Y, PRAMANIK B, PARKER E: Biochemical characterization of the γ-secretase activity that produces β-amyloid peptides. Biochemistry (2001) 40:5049-5055.
67. BARTEN DM, GUSS VL, CORSA JA et al.: β-amyloid reductions in brain, plasma and CSF of a transgenic mouse model of Alzheimer's disease with a γ-secretase inhibitor. Neurobiol. Aging (2004) 25(S2):S82.
68. SIEMERS E, DEAN RA, SATTERWHITE J et al.: Safety, tolerability, and changes in plasma and cerebrospinal fluid amyloid β concentrations after administration of a functional γ -secretase inhibitor in healthy volunteers. Neurobiol. Aging (2004 25 S2):S569-S570.
69. 42 in patients with Alzheimer's disease. Amyloid (2003) 10:1-6.
70. LAHIRI DK, GE Y-W, FARLOW MR: Studies with the memory enhancing drug AIT-082 in PC12 cells. In: Alzheimer's Disease: Advances in Etiology, Pathogenesis and Therapeutics. Iqbal K, Sisodia SS, Winblad B (Eds) Chichester, Wiley (2001):759-767.
71. GRUNDMAN M, FARLOW M, PEAVY G et al.: A Phase I study of AIT-082 in healthy elderly volunteers. J. Mol. Neurosci. (2002) 18:283-293.
72. GRUNDMAN M, CAPPARELLI E, KIM HT et al.: A multicenter, randomized, placebo-controlled, multiple-dose, safety and pharmacokinetic study of AIT-082 (Neotrofin) in mild Alzheimer's disease patients. Life Sci. (2003) 73:539-553.
73. LARNER AJ, DORAN M: Prion diseases: update on therapeutic patents, 1999-2002. Expert Opin. Ther. Patents (2003) 13 1):67-78.
74. TAMAMURA H, KATO T, OTAKA A, FUJII N: Synthesis of potent β-secretase inhibitors containing a hydroxyethylamine dipeptide isostere and their structure-activity relationship studies. Org. Biomol. Chem. (2003) 1:2468-2473.
75. SHUTO D, KASAI S, KIMURA T et al.: KMI-008, a novel β-secretase inhibitor containing a hydroxymethylcarbonyl isostere as a transition-state mimic: design and synthesis of substrate-based octapeptides. Bioorg. Med. Chem. Lett. (2003) 13:4273-4276.
76. CHANG W-P, KOELSCH G, WONG S et al.: In vivo inhibition of brain Aβ level by memapsin 2 (β-secretase) inhibitors. Neurobiol. Aging (2004) 25(S2):S581.
77. WONG PC, CAI H, LAIRD FM et al.: A role for APP and BACE1 in cognition. Neurobiol. Aging (2004) 25(S2):S2.
78. 42 independently of cyclooxygenase activity. Nature (2001) 414:212-216.
79. 42 generation. J. Biol. Chem. (2003) 278 18664-18670.
80. LARNER AJ: Cholinesterase inhibitor use at a cognitive function clinic. Prog. Neurol. Psychiatr. (2004) 8 4):14,18,20.
81. HOCK C, KONIETZKO U, STREFFER JR et al.: Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 38:547-554.
82. GILMAN S, KOLLER M, BLACK RS et al.: Neuropsychological, CSF, and neuropathological effects of Aβ immunotherapy (AN1792) of Alzheimer's disease in an interrupted trial. Neurobiol. Aging (2004) 25(S2):S84.
83. NICOLL JAR, WILKINSON D, HOLMES C, STEART P, MARKHAM H, WELLER RO: Neuropathology of human Alzheimer's disease after immunization with amyloid-β peptide: a case report. Nat. Med. (2003) 9 448-452.
84. FERRER I, BRADA-ROVIRA M, SANCHEZ-GUERRA ML, REY JL, COSTA-JUSSA F: Neuropathology and pathogenesis of encephalitis following amyolid-β immunization in Alzheimer's disease. Brain Pathol. (2004) 14:11-20.